

Post-Transplant Lymphoproliferative Disorder- Pipeline Insight, 2019

<https://marketpublishers.com/r/P79C9A55C5DEN.html>

Date: August 2019

Pages: 60

Price: US\$ 1,250.00 (Single User License)

ID: P79C9A55C5DEN

Abstracts

This report can be delivered to the clients within 24 Hours

"Post-Transplant Lymphoproliferative Disorder- Pipeline Insight, 2019" report by DelveInsight outlays comprehensive insights of present scenario and growth prospects across the indication. A detailed picture of the Post-Transplant Lymphoproliferative Disorder pipeline landscape is provided which includes the disease overview and Post-Transplant Lymphoproliferative Disorder treatment guidelines. The assessment part of the report embraces, in depth Post-Transplant Lymphoproliferative Disorder commercial assessment and clinical assessment of the pipeline products under development. In the report, detailed description of the drug is given which includes mechanism of action of the drug, clinical studies, NDA approvals (if any), and product development activities comprising the technology, Post-Transplant Lymphoproliferative Disorder collaborations, licensing, mergers and acquisition, funding, designations and other product related details.

Post-Transplant Lymphoproliferative Disorder Understanding

Post-transplant lymphoproliferative disease (PTLD) is a rare, but well-known complication of solid organ transplants and hematopoietic stem cell transplantation. PTLD is related to the Epstein-Barr virus and immunosuppression therapy. People who receive these transplants are treated with drugs that suppress the activity of the immune system. Doctors must suppress the immune system to help the body accept the transplant and avoid rejection. Individuals receive these drugs at the time of the transplant (induction therapy) and must remain on these drugs for the rest of their lives (maintenance therapy). Immunosuppressive therapy leaves patients at a greater risk of developing infections and, in some people, of developing post-transplant

lymphoproliferative disease. Early diagnosis and prompt treatment of these disorders are extremely important.

Post-Transplant Lymphoproliferative Disorder Pipeline Development Activities

The report provides insights into different therapeutic candidates in discovery and preclinical, phase 1, phase 2, and phase 3 stage. Drugs under development as a monotherapy or combination therapy are also included. It also analyses key players involved in Post-Transplant Lymphoproliferative Disorder targeted therapeutics development with respective active and inactive (dormant or discontinued) projects with the appropriate reasons if available. Post-Transplant Lymphoproliferative Disorder pipeline report covers 6+ companies. Some of the key players include Atara Biotherapeutics (Tabelecleucel) etc.

The report is built using data and information traced from the researcher's proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university web sites and industry-specific third party sources, etc.

Post-Transplant Lymphoproliferative Disorder Analytical Perspective by DelveInsight

In-depth Post-Transplant Lymphoproliferative Disorder Commercial Assessment of products

This report provides an in-depth Commercial Assessment of therapeutic drugs have been included which comprises of collaborations, Licensing, Acquisition –Deal Value Trends. The sub-segmentation is described in the report which includes Company-Company Collaborations (Licensing / Partnering), Company-Academia Collaborations, and Acquisition analysis in both Graphical and tabulated form.

Post-Transplant Lymphoproliferative Disorder Clinical Assessment of products

The report comprises of comparative clinical assessment of products by development stage, product type, route of administration, molecule type, and MOA type across this indication.

Scope of the report

The Post-Transplant Lymphoproliferative Disorder report provides an overview of therapeutic pipeline activity for Post-Transplant Lymphoproliferative Disorder across the complete product development cycle including all clinical and non-clinical stages

It comprises of detailed profiles of Post-Transplant Lymphoproliferative Disorder therapeutic products with key coverage of developmental activities including technology, collaborations, licensing, mergers and acquisition, funding, designations and other product related details

Detailed Post-Transplant Lymphoproliferative Disorder Research and Development progress and trial details, results wherever available, are also included in the pipeline study

Therapeutic assessment of the active pipeline products by development stage, product type, route of administration, molecule type, and MOA type

Coverage of dormant and discontinued pipeline projects along with the reasons if available across Post-Transplant Lymphoproliferative Disorder

Reasons to Buy

Establish a comprehensive understanding of the current pipeline scenario across Post-Transplant Lymphoproliferative Disorder to formulate effective R&D strategies

Assess challenges and opportunities that influence Post-Transplant Lymphoproliferative Disorder R&D

Develop strategic initiatives by understanding the focus areas of leading companies.

Gather impartial perspective of strategies of the emerging competitors having potentially lucrative portfolio in this space and create effective counter strategies to gain competitive advantage

Get in detail information of each product with updated information on each project along with key milestones

Devise Post-Transplant Lymphoproliferative Disorder in licensing and out licensing strategies by identifying prospective partners with progressing projects for Post-Transplant Lymphoproliferative Disorder to enhance and expand business potential and scope

Our extensive domain knowledge on therapy areas support the clients in decision-making process regarding their therapeutic portfolio by identifying the reason behind the inactive or discontinued drugs

Contents

1. REPORT INTRODUCTION

2. POST-TRANSPLANT LYMPHOPROLIFERATIVE DISORDER

- 2.1. Post-Transplant Lymphoproliferative Disorder Disease Overview
- 2.2. Post-Transplant Lymphoproliferative Disorder History
- 2.3. Post-Transplant Lymphoproliferative Disorder Symptoms
- 2.4. Post-Transplant Lymphoproliferative Disorder Causes
- 2.5. Post-Transplant Lymphoproliferative Disorder Pathophysiology
- 2.6. Post-Transplant Lymphoproliferative Disorder Diagnosis
 - 2.6.1. Diagnostic Guidelines

3. POST-TRANSPLANT LYMPHOPROLIFERATIVE DISORDER CURRENT TREATMENT PATTERNS

- 3.1. Treatment Guidelines

4. POST-TRANSPLANT LYMPHOPROLIFERATIVE DISORDER- DELVEINSIGHT'S ANALYTICAL PERSPECTIVE

- 4.1. In-depth Commercial Assessment
 - 4.1.1. Post-Transplant Lymphoproliferative Disorder companies collaborations, Licensing, Acquisition –Deal Value Trends
 - 4.1.1.1. Assessment Summary
 - 4.1.2. Post-Transplant Lymphoproliferative Disorder Collaboration Deals
 - 4.1.2.1. Company-Company Collaborations (Licensing / Partnering) Analysis
 - 4.1.2.2. Post-Transplant Lymphoproliferative Disorder Acquisition Analysis
- 4.2. Clinical Assessment of Pipeline Drugs
 - 4.2.1. Assessment by Phase of Development
 - 4.2.2. Assessment by Product Type (Mono / Combination)
 - 4.2.2.1. Assessment by Stage and Product Type
 - 4.2.3. Assessment by Route of Administration
 - 4.2.3.1. Assessment by Stage and Route of Administration
 - 4.2.4. Assessment by Molecule Type
 - 4.2.4.1. Assessment by Stage and Molecule Type
 - 4.2.5. Assessment by MOA
 - 4.2.5.1. Assessment by Stage and MOA

5. POST-TRANSPLANT LYMPHOPROLIFERATIVE DISORDER PIPELINE THERAPEUTICS

- 5.1. Late Stage Products (Phase-III)
 - 5.1.1. Comparative Analysis
- 5.2. Mid Stage Products (Phase-II)
 - 5.2.1. Comparative Analysis
- 5.3. Early Stage Products (Phase-I)
 - 5.3.1. Comparative Analysis
- 5.4. Pre-clinical and Discovery Stage Products
 - 5.4.1. Comparative Analysis
- 5.5. Inactive Products

6. POST-TRANSPLANT LYMPHOPROLIFERATIVE DISORDER-PRODUCTS ANALYSIS

- 6.1. Product Profiles
 - 6.1.1. Tabelecleucel- Atara Biotherapeutics
 - 6.1.1.1. Product Description
 - 6.1.1.1.1. Product Overview
 - 6.1.1.1.2. Mechanism of Action
 - 6.1.1.2. Research and Development
 - 6.1.1.2.1. Clinical Studies
 - 6.1.1.2.1.1. Detailed Study Description
 - 6.1.1.2.1.2. Study Results
 - 6.1.1.2.1.3. Clinical Trials: Tabular View
 - 6.1.1.3. Product Development Activities
 - 6.1.1.3.1. Tabulated Product Summary
 - 6.1.1.3.1.1. General Description Table
- To be continued in the report.....

7. RECENT TECHNOLOGIES

8. POST-TRANSPLANT LYMPHOPROLIFERATIVE DISORDER KEY COMPANIES

- 8.1. OPi
- 8.2. Cell Medica
- 8.3. ViGenCell

8.4. Atara Biotherapeutics

8.5. Achillion Pharmaceuticals

8.6. Viracta Therapeutics

9. POST-TRANSPLANT LYMPHOPROLIFERATIVE DISORDER KEY PRODUCTS

9.1. Elsilimomab

9.2. Baltaleucel-T

9.3. VT EBV

9.4. Tabelecleucel

9.5. ACH 126445

9.6. Nanatinostat

10. DORMANT AND DISCONTINUED PRODUCTS

10.1. Dormant Products

10.1.1. Reasons for being dormant

10.2. Discontinued Products

10.2.1. Reasons for the discontinuation

11. POST-TRANSPLANT LYMPHOPROLIFERATIVE DISORDER- UNMET NEEDS

12. POST-TRANSPLANT LYMPHOPROLIFERATIVE DISORDER- FUTURE PERSPECTIVES

13. APPENDIX

14. REPORT METHODOLOGY

14.1. Secondary Research

14.2. Expert Panel Validation

List Of Tables

LIST OF TABLES

Table 1. Post-Transplant Lymphoproliferative Disorder Diagnostic Guidelines

Table 2. Treatment Guidelines

Table 3. Assessment Summary

Table 4. Company-Company Collaborations (Licensing / Partnering) Analysis

Table 5. Post-Transplant Lymphoproliferative Disorder Acquisition Analysis

Table 6. Assessment by Phase of Development

Table 7. Assessment by Product Type (Mono / Combination)

Table 8. Assessment by Stage and Product Type

Table 9. Assessment by Route of Administration

Table 10. Assessment by Stage and Route of Administration

Table 11. Assessment by Molecule Type

Table 12. Assessment by Stage and Molecule Type

Table 13. Assessment by MOA

Table 14. Assessment by Stage and MOA

Table 15. Late Stage Products (Phase-III)

Table 16. Mid Stage Products (Phase-II)

Table 17. Early Stage Products (Phase-I)

Table 18. Pre-clinical and Discovery Stage Products

Table 19. Inactive Products

Table 20. Dormant Products

Table 21. Discontinued Products

List Of Figures

LIST OF FIGURES

- Figure 1. Disease Overview
- Figure 2. History
- Figure 3. Symptoms
- Figure 4. Causes
- Figure 5. Pathophysiology
- Figure 6. Diagnostic Guidelines
- Figure 7. Treatment Guidelines
- Figure 8. Post-Transplant Lymphoproliferative Disorder companies collaborations, Licensing, Acquisition –Deal Value Trends
- Figure 9. Company-Company Collaborations (Licensing / Partnering) Analysis
- Figure 10. Post-Transplant Lymphoproliferative Disorder Acquisition Analysis
- Figure 11. Assessment by Phase of Development
- Figure 12. Assessment by Product Type (Mono / Combination)
- Figure 13. Assessment by Stage and Product Type
- Figure 14. Assessment by Route of Administration
- Figure 15. Assessment by Stage and Route of Administration
- Figure 16. Assessment by Molecule Type
- Figure 17. Assessment by Stage and Molecule Type
- Figure 18. Assessment by MOA
- Figure 19. Assessment by Stage and MOA
- Figure 20. Late Stage Products (Phase-III)
- Figure 21. Mid Stage Products (Phase-II)
- Figure 22. Early Stage Products (Phase-I)
- Figure 23. Pre-clinical and Discovery Stage Products
- Figure 24. Inactive Products
- Figure 25. Dormant Products
- Figure 26. Discontinued Products
- Figure 27. Unmet Needs

KEY COMPANIES

Amgen
OPi
Cell Medica
ViGenCell

Atara Biotherapeutics
Achillion Pharmaceuticals
Mabion
Viracta Therapeutics
bluebird bio

I would like to order

Product name: Post-Transplant Lymphoproliferative Disorder- Pipeline Insight, 2019

Product link: <https://marketpublishers.com/r/P79C9A55C5DEN.html>

Price: US\$ 1,250.00 (Single User License / Electronic Delivery)

If you want to order Corporate License or Hard Copy, please, contact our Customer Service:

info@marketpublishers.com

Payment

To pay by Credit Card (Visa, MasterCard, American Express, PayPal), please, click button on product page <https://marketpublishers.com/r/P79C9A55C5DEN.html>

To pay by Wire Transfer, please, fill in your contact details in the form below:

First name:
Last name:
Email:
Company:
Address:
City:
Zip code:
Country:
Tel:
Fax:
Your message:

****All fields are required**

Customer signature _____

Please, note that by ordering from marketpublishers.com you are agreeing to our Terms & Conditions at <https://marketpublishers.com/docs/terms.html>

To place an order via fax simply print this form, fill in the information below and fax the completed form to +44 20 7900 3970